Skip to main content
Log in

Dosimetry in clinical radionuclide therapy: the devil is in the detail

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

A Correction to this article was published on 11 January 2018

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 11 January 2018

    The above article which was published in Volume 44/ Issue 12 has incorrect page numbers. Instead of 1-3, it should have been 2137-2139.

References

  1. Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the "holy gray". Eur J Nucl Med Mol Imaging. 2007;34(5):772–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Chouin N, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3707-3.

    PubMed Central  Google Scholar 

  3. DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001;39:203–18.

    Article  CAS  PubMed  Google Scholar 

  4. Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41.

    Article  PubMed  Google Scholar 

  5. Pouget J-P, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med. 2001;28:541–61.

    Article  CAS  PubMed  Google Scholar 

  6. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labelled with α-, β-, and auger electron-emitting radionuclides. J Nucl Med. 2006;47:1007–15.

    CAS  PubMed  Google Scholar 

  7. Granzotto A, Devic C, Viau M, Maalouf M, Joubert A, Massart C, et al. Individual susceptibility to radiosensitivity and to genomic instability: its impact on low- dose phenomena. Health Phys. 2011;100(3):282.

    Article  CAS  PubMed  Google Scholar 

  8. Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 2012;13(1):65–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesco Giammarile.

Ethics declarations

Conflict of interest

None.

Research involving human participants and/or animals

This is not a research article.

Informed consent

No informed consent was needed.

Additional information

A correction to this article is available online at https://doi.org/10.1007/s00259-017-3921-z.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giammarile, F., Muylle, K., Delgado Bolton, R. et al. Dosimetry in clinical radionuclide therapy: the devil is in the detail. Eur J Nucl Med Mol Imaging 44, 1–3 (2017). https://doi.org/10.1007/s00259-017-3820-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3820-3

Navigation